Puri Ajay, Byregowda Suman, Gulia Ashish, Patil Vijayraj, Crasto Saniya, Laskar Siddharth
Department of Surgical Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.
Department of Orthopaedic Oncology, Tata Memorial Hospital, HBNI, Mumbai, India.
J Surg Oncol. 2018 Jul;118(1):138-143. doi: 10.1002/jso.25092. Epub 2018 Jun 27.
Establish oncologic safety using 50 Gy to sterilize tumor bearing bone before reimplantation in primary diaphyseal high grade extremity tumors, determine extracorporeal radiotherapy (ECRT) graft survival, and analyze factors that affect union at osteotomy sites.
Seventy non metastatic patients underwent reconstruction with intercalary ECRT grafts sterilized with 50 Gy. Diagnosis included osteosarcoma (38) and Ewing's sarcoma (32). At last follow-up-49 patients were alive, 19 had died and 2 were lost to follow up. Survivors had minimum follow up of 3 years (range 39-127 months).
Ninty one percent metaphyseal osteotomies united without additional intervention compared to 71% diaphyseal osteotomies. Additional small plate at diaphyseal osteotomy apparently reduced incidence of non-union (17% vs 31%) (P = 0.49). Addition of morsellised allograft did not help union. There were seven (10%) local recurrences, all in soft tissue. Seventeen of 69 patients (25%) needed removal of ECRT graft. Five year survival for ECRT graft (removal for all causes) was 79% and 84% (excluding removal for local recurrence).
Reimplanting sterilized tumor bone using 50 Gy for tumor ablation is an easily applicable, oncologically safe, biological reconstruction option for primary diaphyseal extremity tumors.
在原发性骨干高级别肢体肿瘤再植入前,使用50 Gy对带瘤骨进行灭菌以确定肿瘤学安全性,确定体外放疗(ECRT)移植物的存活情况,并分析影响截骨部位骨愈合的因素。
70例非转移性患者接受了用50 Gy灭菌的节段性ECRT移植物重建手术。诊断包括骨肉瘤(38例)和尤因肉瘤(32例)。在最后一次随访时,49例患者存活,19例死亡,2例失访。存活者的最短随访时间为3年(范围39 - 127个月)。
91%的干骺端截骨无需额外干预即可愈合,而骨干截骨的愈合率为71%。骨干截骨处额外使用小钢板明显降低了不愈合的发生率(17%对31%)(P = 0.49)。添加碎骨同种异体骨对骨愈合没有帮助。有7例(10%)局部复发,均发生在软组织。69例患者中有17例(25%)需要取出ECRT移植物。ECRT移植物的5年生存率(因各种原因取出)为79%,排除因局部复发取出后的生存率为84%。
使用50 Gy对肿瘤进行消融后再植入灭菌的肿瘤骨,是原发性骨干肢体肿瘤一种易于应用、肿瘤学安全的生物重建选择。